Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries
© Kebriaeezadeh et al.; licensee BioMed Central Ltd. 2013
Received: 3 September 2012
Accepted: 20 June 2013
Published: 28 June 2013
So far, no detailed study of the Iranian pharmaceutical market has been conducted, and only a few studies have analyzed medicine consumption and expenditure in Iran. Pharmaceutical market trend analysis remains one of the most useful instruments to evaluate the pharmaceutical systems efficiency. An increase in imports of medicines, and a simultaneous decrease in domestic production prompted us to investigate the pharmaceutical expenditure structure. On the other hand, analyzing statistics provides a suitable method to assess the outcomes of national pharmaceutical policies and regulations.
This is a descriptive and cross-sectional study which investigates the Iranian pharmaceutical market over a 13-year period (1997–2010). This study used the Iranian pharmaceutical statistical datasheet published by the Iranian Ministry of Health. Systematic searches of the relevant Persian and English research literature were made. In addition, official government documents were analyzed as sources of both data and detailed statements of policy.
Analysis of the Iranian pharmaceutical market in the 13-year period shows that medicine consumption sales value growth has been 28.38% annually. Determination of domestic production and import reveals that 9.3% and 42.3% annual growth, respectively, have been experienced.
The Iranian pharmaceutical market has undergone great growth in comparison with developing countries and the pharmerging group, and the market is expanding quickly while a major share goes to biotechnology drugs, which implies the need to commercialization activities in novel fields like pharmaceutical biotechnology. This market expansion has been in favor of imported medicine in sales terms, caused by the reinforcement of suspicious policies of policy makers that necessitates fundamental rearrangements.
KeywordsPharmaceutical market trends Therapeutic categories Pharmaceutical biotechnology Commercialization
Total expenditure on health in Iran is increasing, while the public sector’s share is decreasing. Private sector expenditure as out-of-pocket payment is remarkably high as it accounts for more than 50% of the whole expenditure . The modern Iranian pharmaceutical system commenced 100 years ago with the opening of the first modern-style pharmacy by German, French, and Austrian pharmacists in Tehran. Pharmacy training was initiated by European instructors at Darolfonoon, which was remodeled with the inauguration of the Tehran Faculty of Pharmacy in 1934 which undertook a very important role in the Iranian pharmaceutical industry. Established in 1946, Abidi was the first Iranian pharmaceutical company, followed by Tolid Darou and Darou Pakhsh in 1958 and 1963, respectively . After the Islamic revolution, two major motions caused fundamental changes: nationalization of the pharmaceutical industries, and generic scheme. Governmental industry privatization and transition to the semi-governmental sector was one of the major actions taken by the government in the 1988 to 1993 period. This study examines the present situation of the pharmaceutical system in Iran, including the domestic production companies, importing companies, distribution, regulations, human resources in the pharmaceutical system, and market trend analysis .
Present situation of the Iranian pharmaceutical industry
Ten top domestic production pharmaceutical companies in Iran; 2009-2010
Cumulative market share
Darou Pakhsh Pharma
Jaber Ebne Hayyan
Major holdings in domestic pharmaceutical production in Iran; 2009-2010
Cumulative market share
Tamin Investment Corporation
Sobhan Pharmaceutical Group
Tehran Chimi Corporation (Private)
Ten top importer companies in Iran; 2009-2010
Cumulative market share
Gostaresh Bazargani Daroupakhsh
Kavosh Gostar Darou
There were 35 nationwide drug distribution companies, among which the first four distribute approximately 70% of the entire market’s drugs. All major holdings have their own nationwide drug distribution companies that are ranked in the top four. HHI was 1387, which was significantly higher than that of the domestic production.
Passed in 1955, the medicine, drug, food, and drink affairs law act is the cornerstone for the current pharmaceutical procedures in Iran. Most of the bylaws and ordinances are designed and approved in the drug affairs department .
Production, importation, and distribution of medicinal products are performed under strict control by the authorities, and involve registration and licensure by the food and drug organization (formerly, Undersecretary of Food and Drug).
Medicine price is controlled by the food and drug organization through pricing commission regulations in a cost plus basis through comparison with selected companies according to published regulations.
Medicine cost reimbursement is mainly undertaken by three major organizations: Social Security Organization (public), Medical Services Insurance Organization (governmental), and Medical Insurance Services Organization of Armed Forces (governmental), all of which reimburse the cheapest medicine registered. The emerging supplementary insurance companies are putting constraints on pharmaceutical expenditure. There is a positive list of medicines fully covered by the government that contains specialty drugs.
Pharmacists are considered a major source for the pharmaceutical system. Most of the 13000 pharmacist society members are involved in pharmacies. About 6% of the pharmacists work in the industry. In the industry itself, less than 2% of the trained and scientific workforce is engaged in research and development.
Active pharmaceutical ingredients
A growing number of companies are engaged in the production of Active Pharmaceutical Ingredient (API). Each holding has its own API-producing branch, and there are more than 30 companies engaged in production of APIs. Formal policies of the Ministry of Health actively promote motions towards independence in the API industry. Companies active in the field of API production are mainly possessed by the private sector, contrary to the finished products and distribution companies .
This is a descriptive and cross-sectional study which investigates the Iranian pharmaceutical market over a 13-year period (1997–2010). This study used the Iranian pharmaceutical statistical datasheet published by the Iranian Ministry of Health. Drug consumption statistics are collected by the Food and Drug Organization (FDO) through the data received from the drug distribution companies. All distribution companies deliver their data on drug sales to the pharmacies as a unified format to the food and drug organization on a monthly basis. That data, after revision, is published as the Iranian pharmaceutical statistical datasheet yearly as sales volume (by unit) for any medicine delivered, and cost per medicine unit. Although that data does not represent real drug consumption and the subsidy paid by the government and only reveals the sales of drug to the pharmacies, it is the most unique and convenient method to monitor the pharmaceutical market. Systematic searches of the relevant Persian and English research literature were made, using electronic databases in addition to written reports. Official government documents were also analyzed as sources of data and detailed statements of policy. Different sources, such as statistics published by the Iranian Ministry of Health, pharmaceutical production companies syndicate, and the national medicine assemblies were also researched for statistics and data on medicine consumption in a domestic production and importation separation basis, production and importation statistics, pharmaceutical expenditure, medicine consumption per capita, and drug utilization by sales value in different therapeutic categories.
Per capita drug consumption sales value
Per capita value of domestic pharmaceutical medicine consumption
This index has reached $22.86 from $2.05 in 1997, with a total and an annual growth of 1018% and 10.8%, respectively (R2: 0.9397).
Per capita value of the imported medicine consumption
This index has reached $11.57 from $0.24 in 1997, with a total growth of 4373% (R2: 0.8907).
Average sales value of the medicines by unit
Drug consumption by therapeutic categorization (by ATC codes)
Iran’s demographic structure and population growth;
increased insurance coverage of the population;
increased level of income and gross domestic product (GDP) per capita;
incidence of new diseases and epidemiologic transition, e.g. types of cancer and multiple sclerosis;
intentionally lowered medicine price; and
medical sciences advances.
In the period under investigation, accessibility to health services and insurance coverage has grown remarkably, possibly as a result of GDP growth. The government has approached the medicine accessibility positively, and a number of medicines have been included in the medicine list. However, insurance coverage has not expanded simultaneously and proportionately. Health sector budget share in the GDP did not develop acceptably, causing a drastic increase in the public’s out-of-pocket payment. Insurance coverage expansion was through three major organizations: the Social Security Organization, Medical Services Insurance Organization, and Medical Insurance Services Organization of Armed Forces. The universal insurance coverage act obliges the population to register for an insurance service which contributes to the goal. Iranian pharmaceutical industries mostly manufacture traditional medicines, and deficiency in the investments needed for monoclonal antibodies and other biotechnology-derived products, as a consequence, helped the higher share of imported medicine. The Iranian pharmaceutical industry’s private sector has not yet developed as much as required. More than 70% of the domestic industries are owned by the government and its related bodies or the public organizations. As evidenced by the two existing biotechnology companies, both of which are privately-owned, privatization can lead to greater sustainable development in domestic industries [6, 7]. Currently, total pharmaceutical market value is about $3.2 billion, or as much as $4-4.5 billion according to some estimates on the real market size . The present difference between real and estimated value is attributed to the price suppression policies of the authorities . It should also be noted that national currency has experienced a drastic devaluation against USD. Iran experiences an average growth rate of 28.38%, which is significantly more than developing countries such as China and India which have around 11 to 15% growth [10, 11]. The results show that the domestic production sales value has grown, but not in concordance with that of the imported medicine sales value. The results also imply that the current pharmaceutical policies are in favor of imports, as the slope of the import and domestic production lines illustrate. The rise in Iranian pharmaceutical expenditure is expected to continue at a significant, even higher rate than expected from developing countries, based on factors mentioned above and the deliberate deficiencies of pharmaceutical policy [12, 13]. Medicines are regarded as both public and industry goods. Iranian patients are entitled to have access to high-quality, timely, and cost-effective medicine [14, 15]. The Iranian pharmaceutical market is predicted to maintain its growth for years to come. Currently, 20% of Iran’s total health expenditure, on average, goes on medicine (reimbursed by the insurance organizations, based on their reports to the supreme insurance council for last year). Antibiotics, antineoplastics and immunomudulating agents (medicines mostly used for organ transplantation rejection prohibition), antidiabetics, and alimentary tract medications gain the most value in the market (Figure 5). Regarding sales volume, analgesics, antibiotics, and second generation antidiabetics are the best sellers. Investigating the mostly used products among the two top categories it is obvious that pharmaceutical biotechnology derived medicines such as proteins and monoclonal antibodies take major positions (results not presented). Considering the items mentioned, it is concluded that new and high tech medicines are seizing a large share of the market; which should incite policy makers to change for the better. If the market continues its growth, a great financial load will be imposed on the health system. Iran contains nearly 1% of the world’s population, but only about 0.3% of the world market, so if the two are in an agreement, Iran should assume $7-8 billion in 2010, and $10-12 billion in 2020. Generic medicine use is an important component of the government’s health plan that was obligatory through the generic scheme shortly after the revolution. The policy assisted the country pass the constraints of the 1980s, but vitally restricted research and development in the domestic industry, while exerting severe price containment policies . Current issues of interest for the Iranian pharmaceutical market include a rise in imports and simultaneous fall in domestic production. Low rates of investment, capital asset substitution, scarce attention to modern technologies like pharmaceutical biotechnology, and a branded medicine market are possible reasons for this domestic medicine market shrinkage [17, 18]. The investment activity of pharmaceutical companies is dependant mainly on product demand, profits, technological developments, and capital availability. It is vital to notice the steady decrease in investment rate for capital equipment replacement. This is associated with the market shift towards imported medicines and the lack of well-designed, long-term policies to support the domestic pharmaceutical industry that would potentiate reasonable conditions to encourage domestic production . Meanwhile vast research projects have been conducted in the universities and research centers but few of them have been commercialized into medicines. Performing studies aligned with the needs of the biopharmaceutical industry could be seen as a choice. Policy makers and authorities could contribute the national production capabilities by establishing the basements to commercialize the researches, revising the policies, forming close relationships and cooperative committees with the biopharmaceutical industries and applying evidence based decision making procedures.
The absence of significant basic and applied biopharmaceutical research that can result in industrial breakthroughs and attain competitive advantage in Iran has induced a state of regression in the domestic industry that has accelerated a drain on the capital and energy of the industry. Such conditions, along with price suppression, increase imports [20, 21]. It is advised that policy makers take all necessary measures towards establishing an appropriate pharmaceutical business environment that favors domestic production, as well as controlling rising expenditure in the pharmaceutical sector . We can conclude that the average value of imported medicine per unit is growing, which suggests technological content is in continuous improvement in comparison with domestic ones [23–25]. Medicine consumption per capita shows that this index is high in Iran. Therefore, it is proposed that conducting applied research projects ordered by the biopharmaceutical industries along with preparing the requirements for commercialization of novel fields like pharmaceutical biotechnology which assigns a great share in the national pharmaceutical expenditure be in the top agenda.
Active Pharmaceutical Ingredient
Food and Drug organization
Gross Domestic Product
Anatomical Therapeutic Chemical Classification System.
The authors are thankful to the Food and Drug Organization (FDO) and Department of Planning and Statistics for providing the data for the project.
- Ensor T, Weinzierl S: Regulating health care in low- and middle-income countries: Broadening the policy response in resource constrained environments. Soc Sci Med. 2007, 65: 355-366.View ArticlePubMedGoogle Scholar
- Kebrieezadeh A, Eslamitabar S, Khatibi M: Iranian pharmaceutical law and regulations. 2009, Tehran: Razico, 2Google Scholar
- Reinhardt UE: An information infrastructure for the pharmaceutical market. Health Aff. 2004, 23 (1): 107-112.View ArticleGoogle Scholar
- Davari M, Walley T, Haycox A: Pharmaceutical policy and market in Iran: past experiences and future challenges. J Pharm Health Serv Res. 2011, 2: 47-52.View ArticleGoogle Scholar
- Cheraghali AM: Pharmacoeconomics: An Effective Tool for Prioritization in Iran Healthcare System. Iranian J Pharm Res. 2008, 7 (2): 89-91.Google Scholar
- Kebriee-zadeh A: Overview of National Drug Policy of Iran. IJPR. 2003, 1-2.Google Scholar
- Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A: Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence. Health Policy. 2011, 100: 134-143.View ArticlePubMedGoogle Scholar
- Cheraghali AM: Pharmaceutical Market. IJPR. 2006, 1: 1-7.Google Scholar
- Rusu A, Kuokkanen K, Heier A: Current trends in the pharmaceutical industry - A case study approach. Eur J Pharm Sci. 2011, 44: 437-440.View ArticlePubMedGoogle Scholar
- Drews J: Strategic trends in the drug industry. Drug Discov Today. 2003, 8 (9): 411-420.View ArticlePubMedGoogle Scholar
- Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M: Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the National Drug Selecting Committee in Iran. BMC Int Health Hum Rights. 2005, 5: 5-PubMed CentralView ArticlePubMedGoogle Scholar
- Kontozamanis V, Mantzouneas E, Stoforos C: An overview of the Greek pharmaceutical market. Eur J Health Econ. 2003, 4: 327-333.View ArticlePubMedGoogle Scholar
- Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Rompay MV: Trends in alternative medicine use in the United States, 1990–1997, results of a follow-up national survey. JAMA. 1998, 280 (18): 1569-1575.View ArticlePubMedGoogle Scholar
- Tokgöz T: The Turkish pharmaceutical market. JGM. 2010, 7: 270-274.Google Scholar
- Tetteh EK: Providing affordable essential medicines to African households: The missing policies and institutions for price containment. Soc Sci Med. 2008, 66: 569-581.View ArticlePubMedGoogle Scholar
- Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R: Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009, 373: 240-249.View ArticlePubMedGoogle Scholar
- Oortwijn W, Mathijssen J, Banta D: The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Health Policy. 2010, 95: 174-184.View ArticlePubMedGoogle Scholar
- Kutaini D: Pharmaceutical industry in Syria. J Med Life. 2010, 3 (3): 348-350.PubMed CentralPubMedGoogle Scholar
- Ghislandi S, Krulichova I, Garattini L: Pharmaceutical policy in Italy: towards a structural change?. Health Policy. 2005, 72: 53-63.View ArticlePubMedGoogle Scholar
- Merkur S, Mossialos E: A pricing policy towards the sourcing of cheaper drugs in Cyprus. Health Policy. 2007, 81: 368-375.View ArticlePubMedGoogle Scholar
- Aaserud M, Dahlgren AT, Kosters JP, Oxman AD, Ramsay C, Sturm H: Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev. 2006, 2: -
- Lockhart M, Babar ZUD, Garg S: Evaluation of policies to support drug development in New Zealand. Health Policy. 2010, 96: 108-117.View ArticlePubMedGoogle Scholar
- Kisa A: Analysis of the pharmaceuticals market and its technological development in Turkey. Int J Technol Assess Health Care. 2006, 22 (4): 537-542.View ArticlePubMedGoogle Scholar
- Abdollahiasl A, Kebriaeezadeh A, Nikfar S, Farshchi A, Ghiasi G, Abdollahi M: Patterns of antibiotic consumption in Iran during 2000–2009. Int J Antimicrob Agents. 2011, 37: 489-490.View ArticlePubMedGoogle Scholar
- Abdollahiasl A, Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M: A model for developing a decision support system to simulate national drug policy indicators. Arch Med Sci. 2011, 5: 744-746.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.